Ji Xing: building a CV pipeline for Chinese patients
Emerging Company Profile: Ji Xing to advance CV portfolio with $40M series B and Merck vet at the helm
With the appointment of longtime Merck veteran Joseph Romanelli as CEO and the close of its $40 million series B, Ji Xing is poised to advance and expand its China-focused cardiovascular pipeline.
Romanelli joins Ji Xing Pharmaceuticals Ltd. following a 25-year tenure at Merck & Co. Inc. (NYSE:MRK); he had served as president of MSD China since 2016, overseeing the approval and launch of multiple products in China including anti-PD-1 mAb Keytruda pembrolizumab and HPV vaccines Gardasil and Gardasil 9. He succeeds Peter Fong, who will continue in his role as head of company creation at RTW Investments, Ji Xing’s sole investor. ...